Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Slides:

Advertisements

Similar presentations

Elizabeth A. David, MD, David T

Advertisements

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Coronary Artery Bypass for Heart Failure in Ischemic Cardiomyopathy: 17-Year Follow- Up Marco Pocar, MD, PhD, Andrea Moneta, MD, Adalberto Grossi, MD,

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Thomas J. Birdas, MD, Richard P. M

True Negative Predictive Value of Endobronchial Ultrasound in Lung Cancer: Are We Being Conservative Enough? Bryan A. Whitson, MD, PhD, Shawn S. Groth,

Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis Amgad El-Sherif, MD, William E. Gooding, MS,

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Joshua E. Rosen, BASc, Hari B

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Pacemaker Therapy After Tricuspid Valve Operations: Implications on Mortality, Morbidity, and Quality of Life Janne J. Jokinen, MD, Anu K. Turpeinen,

Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Robert E. Freundlich, MD, MS, Michael D. Maile, MD, MS, Mark M

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Surgical Treatment of Metachronous Second Primary Lung Cancer

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database Seth B. Krantz, MD, Waseem Lutfi, BS, Kristine Kuchta, MS, Chi-Hsiung.

Management of Cervical Esophageal Injury After Spinal Surgery

Invasive adenocarcinoma with bronchoalveolar features: A population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma Bryan.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Alex K. Bryant, BS, Robert C. Mundt, HSDG, Ajay P. Sandhu, MD, James J

Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma Ichiro Yoshino, MD, PhD, Daigo Kawano, MD, Taro Oba, MD, Koji.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Video-Assisted Thoracoscopic Surgery is More Favorable Than Thoracotomy for Resection of Clinical Stage I Non-Small Cell Lung Cancer Bryan A. Whitson,

Endobronchial Ultrasound-Guided Fine-Needle Aspiration of Mediastinal Lymph Nodes: A Single Institution's Early Learning Curve Shawn S. Groth, MD, Bryan.

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Understanding Mortality as a Quality Indicator After Esophagectomy

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Carcinoma of the esophagus: Prognostic significance of histologic type

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Risk Factors for Local Recurrence and Optimal Length of Esophagectomy in Esophageal Squamous Cell Carcinoma Chang Hyun Kang, MD, PhD, Yoohwa Hwang, MD,

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Serratus Anterior Transposition Muscle Flaps for Bronchial Coverage: Technique and Functional Outcomes Shawn S. Groth, MD, Bryan A. Whitson, MD, PhD,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Mark W. Hennon, MD, Elisabeth U

Yinin Hu, MD, Timothy L. McMurry, PhD, Kristen M. Wells, PhD, James M

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

Lung Transplantation for Idiopathic Pulmonary Fibrosis

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Alexander H. Moskovitz, MD, Nabil P

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy Arjun Pennathur, MD, Andrew Farkas, BA, Alyssa.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Thirty-Day Mortality Underestimates the Risk of Early Death After Major Resections for Thoracic Malignancies Robert R. McMillan, MD, MPH, Alexandra Berger,

Kathleen E. Simpson, MD, Elizabeth Pruitt, MSPH, James K

Presentation transcript:

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha M. Rueth, MD, James S. Hodges, PhD, Elizabeth B. Habermann, PhD, MPH, Rafael S. Andrade, MD, Jonathan D'Cunha, MD, PhD, Michael A. Maddaus, MD The Annals of Thoracic Surgery Volume 90, Issue 2, Pages 375-382 (August 2010) DOI: 10.1016/j.athoracsur.2010.04.100 Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Cancer-specific survival curve (solid line) for patients with early stage (I and II) non-small cell lung cancer. (A) Representative (dotted) tangent lines demonstrate that the risk of death (slope of the curve) changes throughout the course of follow-up. (B) For example, the risk of dying of cancer in the subsequent 5 years is greater for patients at the time of cancer diagnosis (Δ1) than for patients 3 years after diagnosis (Δ2). Data from the Surveillance, Epidemiology, and End Results Database (1988–2005). The Annals of Thoracic Surgery 2010 90, 375-382DOI: (10.1016/j.athoracsur.2010.04.100) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Patients included in and excluded from the study. (NSCLC = non-small cell lung cancer; SEER = Surveillance, Epidemiology, and End Results.) The Annals of Thoracic Surgery 2010 90, 375-382DOI: (10.1016/j.athoracsur.2010.04.100) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Five-year cancer-specific survival rates, with error bars indicating 95% confidence intervals (vertical axis) conditioned on surviving 0 to 10 years after lobectomy (horizontal axis). The Annals of Thoracic Surgery 2010 90, 375-382DOI: (10.1016/j.athoracsur.2010.04.100) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Competing risks curves for the probability of the following outcomes: surviving (solid line), cancer-specific mortality (dotted line), cardiovascular disease-specific mortality (dashed line), and death from other causes (dotted and dashed line) at (A) the time of diagnosis and conditioned on living (B) 1 year, (C) 3 years, (D) 5 years, and (E) 7 years after lobectomy. The p values are for tests comparing the conditional probabilities of cancer-specific and cardiovascular disease-specific mortality within 5 years. The Annals of Thoracic Surgery 2010 90, 375-382DOI: (10.1016/j.athoracsur.2010.04.100) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Fig 5 Analysis demonstrating the year at which the probability (P) of dying of cancer is not significantly different (p > 0.01) from the probability of dying of cardiovascular (CV) disease (vertical axis) for each of the following subgroups: (A) age, (B) race, (C) sex, (D) pathologic tumor (T) stage, and (E) histology. (Adeno = adenocarcinoma; BAC = bronchoalveolar carcinoma; squam = squamous cell carcinoma.) The Annals of Thoracic Surgery 2010 90, 375-382DOI: (10.1016/j.athoracsur.2010.04.100) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions